Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRONG: Safety of Fixed-Dose Durvalumab +/- Tremelimumab in Advanced Solid Malignancies
NCT03084471Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 8
01
Overview
Phase 3, open-label trial of durvalumab in malignant solid tumor (2 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events of Special Interest up to 3 years. Started Jun 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT03084471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084471.